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Animal Model of Sclerotic Skin. IV: Induction of Dermal
Sclerosis by Bleomycin is T Cell Independent
To the Editor:
Systemic sclerosis (SSc) is a chronic connective tissue disorder
characterized by excessive collagen production by activated
®broblasts resulting in the deposition in the dermis (Krieg and
Meurer, 1988). Although a number of attempts have been
made, the pathogenesis of SSc still remains unknown. Previous
studies have suggested immunologically mediated mechanisms
involving immunocytes in®ltrating in the dermis. In its early
stage, SSc is associated with intense mononuclear cell in®ltration
(Fleishmajer et al, 1977; Roumm et al, 1984), which is mainly
composed of T lymphocytes, mast cells, and monocyte/
macrophages, along with a smaller number of B cells and
plasma cells. Several in¯ammatory or ®brogenic cytokines
released from T cells and monocyte/macrophages are suggested
to play an important role in the induction of tissue ®brosis in
the affected sites. Bleomycin (BLM) is an antitumor antibiotic
used for the therapy of a variety of cancers. It is well known
that pulmonary ®brosis can be induced in patients treated with
BLM as a side-effect. Thus, BLM-induced lung ®brosis is an
established animal model, resembling human pulmonary ®brosis
histologically and biochemically (Adamson and Bowden, 1974;
Aso et al, 1976; Chandler, 1990). In vivo T cell depletion with
anti-T cell antibodies has been shown to either reduce or
completely abrogate BLM-induced pulmonary ®brosis (Thrall et
al, 1980; Piguet et al, 1989). On the other hand, results of
athymic nude mice lacking functional T lymphocytes have been
controversial. One study showed histologically similar ®brosis in
nude, euthymic mice after BLM treatment (Szapiel et al, 1979),
whereas another study showed that BLM was not ®brogenic in
nude mice (Schrier et al, 1983). On the contrary, a recent study
has demonstrated that BLM-induced lung ®brosis occurred in
C57BL/6 SCID and (C57BL/63CB.17)F1SCID mice compar-
able with that seen in wild-type mice, suggesting that the initial
induction of lung ®brosis is lymphocyte-independent (Lake-
Bullock et al, 1999). We have recently established a mice model
for scleroderma by repeated local injections of BLM (Yamamoto
et al, 1999a). In this study, in order to determine the role of
lymphocytes in the induction of dermal sclerotic lesions, we
examined whether dermal sclerosis can be induced in SCID
mice using our method. Speci®c pathogen-free, 6-wk-old,
female BALB/C mice (wild-type) and age- and sex-matched
BALB/C SCID mice (weighing about 20 g) were purchased
from Clea (Tokyo, Japan), and maintained with food and water
ad libitum. BLM was dissolved in phosphate-buffered saline
(PBS) at a concentration of 100 mg per ml, and sterilized by
®ltration (0.2 mm). One hundred microliters of BLM or PBS
were injected subcutaneously into the shaved back of mice
every other day for 4 wk with a 27-gauge needle. The back
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skins were removed on the next day of the ®nal treatment, and
cut into two. One was ®xed in 10% formalin solution and
embedded in paraf®n, and the other was snap-frozen in OCT
compound (Miles, Elkhart, IN) in liquid nitrogen and stored
immediately at ±80°C. Collagen was detected by Masson
trichrome stain. Mast cells were identi®ed by toluidine blue
stain (pH 7.0), and cells containing metachromatic cytoplasmic
granules were counted under high magni®cation of a 3400
power-®eld (HPF) of a light microscope in 10 ®elds, and the
mean number was calculated. For collagen assay, 6 mm punch
biopsy specimens were excised from the shaved back skin, and
stored at ±80°C. Collagen deposition was estimated by deter-
mining the total collagen content of the skin using the Sircol
Collagen Assay kit (Biocolor, Northern Ireland) according to
the manufacturer's instructions. The biopsies were homogenized
in 0.5 M acetic acid, and 1 ml of Sircol dye reagent that binds
to collagen was added to each sample and then mixed for
30 min. After centrifugation, the pellet was suspended in 1 ml
of the alkali reagent included in the kit and assessed
colorimetrically at 540 nm by a spectophotometer. Collagen
standard solutions were utilized to construct a standard curve.
Results were expressed as a parcentage compared with mice
that received only PBS injection. In each experiment, at least
six mice were examined. Results were expressed as
mean 6 SD. Signi®cance testing was analyzed using the
Mann±Whitney U test. A p value < 0.05 was considered to
be signi®cant. Subcutaneous injections of BLM for 4 wk
induced marked dermal sclerosis in SCID mice, as well as
control BALB/C mice, which histologically showed thickened
and homogenous collagen bundles (Fig 1A±D). Cellular in®l-
trates were noted in the lower dermis. Dermal thickness was
similarly induced by BLM treatment, as compared with PBS
treatment, in both strains. Keratinous cysts were noted in some,
but not all, of the SCID mice examined. Masson trichrome
stain showed diffuse positive staining in the sclerotic lesional
skin in both strains (not shown). Toluidine blue stain revealed
an increased number of mast cells, containing degranulated mast
cells, around the sclerotic lesional skin as the dermal sclerosis
developed in both control and SCID mice after BLM
treatment. Results of the number of total mast cells in the
sclerotic skin after BLM treatment were signi®cantly higher
than that of PBS-treated skin in both control BALB/C mice
Figure 1. Histologic examination. BALB/C mice after local injections of (A) BLM (100 mg per ml) and (C) PBS for 4 wk. BALB/C SCID mice
were similarly treated by (B) BLM (100 mg per ml) and (D) PBS for 4 wk. Magni®cation; 3180.
Figure 2. Results of collagen contents in the skin after BLM
treatment. Mice were treated by PBS or BLM (100 mg per ml) for
4 wk, and collagen contents in the 6 mm punch biopsied skin samples
were evaluated comparing between mice treated with PBS (h) and BLM
(j).
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(2.9 6 0.7/HPF in PBS-treated skin vs 15.2 6 2.2/HPF in
BLM-treated skin; p < 0.005) and SCID mice (3.2 6 0.6/HPF
in PBS-treated skin vs 15.8 6 2.6/HPF in BLM-treated skin;
p < 0.005). In the sclerotic skin induced by 4 wk injections of
BLM, collagen content in the skin was signi®cantly increased as
compared with that in PBS-treated mice, which reached up to
2-fold increase in both strains (224% 6 21% of control in
BALB/C mice; p < 0.05, and 230% 6 25% of control in SCID
mice; p < 0.05) (Fig 2). In the lesional skin of SSc, T cells,
predominantly CD4+ T cells, are the major lymphocytes
(White, 1994). Increased number or an activated state of T
cells are also present in involved skin in the animal model of
scleroderma, as in human SSc. In hereditary avian scleroderma,
University of California at Davis line-200 chickens have a
defect in thymic maturation of T cells and develop severe
perivascular T cell in®ltration of the skin and internal organs
(Gruschwitz et al, 1991). An important role of lymphocytes in
the pathogenesis of tight skin (Tsk) mice has been suggested
through adoptive transfer experiments (Walker et al, 1989;
Phelps et al, 1993). In addition, it was also shown that the
progression of dermal ®brosis was markedly suppressed in Tsk/
+, CD4±/± mice, which demonstrates a distinct role of CD4
lymphocytes in the development of skin ®brosis (Wallace et al,
1994). On the other hand, a recent study indicates that
pulmonary ®brosis was equally induced by BLM in C57BL/6
and its SCID counterparts, suggesting that T cells are not
required for the induction of BLM-induced lung ®brosis (Lake-
Bullock et al, 1999). Our study also showed that dermal
sclerosis can be induced by BLM treatment in SCID mice as
well, and furthermore, the period needed for the development
of dermal sclerosis was not retarded as compared with control
BALB/C mice. In®ltrating mast cells were increased in number
after BLM treatment in both control and SCID mice, as
compared with PBS-treated skin; however, we have recently
demonstrated that dermal sclerosis is inducible by BLM in the
absence of mast cells in genetically mast cell de®cient WBB6F1-
W/Wv mice, as well as control littermates (Yamamoto et al,
1999b). Our results suggest that participation of T cells or
B cells, as well as mast cells, are not an essential requirement
for the development of BLM-induced dermal sclerosis. It is
shown that BLM directly affects on ®broblasts to upregulate
collagen synthesis in vitro (Clark et al, 1980). Our unpublished
data also indicate that BLM upregulates type I collagen and
®bronectin mRNA in cultured normal skin ®broblasts
(Yamamoto et al, manuscript submitted). BLM exposure to rat
lung ®broblast cultures results in elevated TGF-b mRNA
synthesis, TGF-b mRNA steady-state levels, and TGF-b protein
(Breen et al, 1992). Increased TGF-b mRNA transcription is
followed by TGF-b mRNA accumulation and TGF-b protein,
which is followed by increased procollagen gene transcription
(Breen et al, 1992). A recent study showed that TGF-b is a
mediator of the ®brotic effect of BLM at the transcriptional
level and that the TGF-b response element is required for BLM
stimulation of the pro a1(I) collagen promoter (King et al,
1994). These results show that BLM increases extracellular
matrix production even without the involvement of immuno-
cytes.
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